Navigation Links
Mylan Reports Adjusted Diluted Cash EPS of $0.11 for the Quarter
Date:2/27/2008

k Generics' contribution to our growth. The strong performance of Merck Generics bolstered the solid nine-month results of the legacy Mylan operations. Further, these strong results were achieved while tremendous progress was made, both on the integration and on achieving our targeted synergies. Looking forward, we will continue to execute on our strategies and leverage the additional opportunities and benefits that we see from the global platform created by the combination of Mylan, Merck Generics and Matrix."

Synergy Update

Mylan confirmed that it expects to realize its stated $100 million synergy target for the Merck Generics acquisition for 2008 (exclusive of one time costs) and it is on track to meet or exceed the targeted recurring annual synergies of $300 million by the end of 2010, as outlined by the Company during its investor day on October 3, 2007.

To achieve these results, the Company announced that it has initiated the necessary actions within research and development (R&D) and manufacturing. The actions announced today are expected to yield 75% of the overall $300 million annual synergy target by the end of 2010.

Heather Bresch, Chief Operating Officer and Chief Integration Officer, said: "We are well ahead of our implementation schedule. Our efforts to date extend across all areas of the new combined company, including strengthening our leadership and organizational infrastructure, ensuring effective separation from Merck KGaA, building Mylan's brand equity globally and, most importantly, realizing value from the New Mylan by delivering on our synergy targets."

Specific steps being taken to rationalize and optimize our global manufacturing and research and development platforms include:

-- Discontinue manufacturing and R&D at Genpharm in Canada. The

Commercial Operations, Packaging Unit, Quality Control Laboratory,

Biopharm Department, Supply Chain Functions, and Regulatory Affairs at
'/>"/>

SOURCE Mylan Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine news :

1. Mylan Announces Appointment of Jagdish Dore as CEO and Managing Director of Matrix Laboratories
2. Mylan Revises Timing of Its Financial Results Conference Call for the Quarter and Nine Months Ended Dec. 31, 2007, to 5 p.m. ET
3. Mylan Confirms Its Matrix Design Fentanyl Patch Is Not Included In the Widespread Recall Announced February 12th
4. Mylan Restores Availability of Generic Levothyroxine in Florida
5. Mylan Schedules Financial Results Conference Call and Live Webcast for the Quarter and Nine Months Ended Dec. 31, 2007
6. Mylan Declares Quarterly Preferred Stock Dividend
7. Mylan Provides Update Relating to Ongoing Lorazepam and Clorazepate Litigation
8. Mylan Announces Final FDA Approval for Cetirizine Hydrochloride Tablets
9. Mylan Sets Date of 2008 Annual Meeting
10. Mylan Receives $26.2 Million From Exercise of Overallotment Option of Common Stock
11. Mylan Announces Tentative FDA Approval Under PEPFAR for Tenofovir Disoproxil Fumarate Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2014)... Ticket Down is a reliable ... in NYC. This popular ticket exchange has ... day session, evening session, courtside seats, grandstand seats, general ... Grand Slam Tournament. , The 2014 U.S. Open Tennis ... Tennis Championship: Men's/Women's 3rd Round - Session 11 Tickets ...
(Date:8/30/2014)... 2014 Acne is a common problem millions of ... nothing more than a daily nuisance, for some, it can have ... acne can even lead to dramatic mood swings and depression. ... to clear up their skin. In some cases, that can make ... trial and error, those on a quest for clearer skin can ...
(Date:8/30/2014)... 2014 Hundreds of Byetta lawsuits ( ... move forward in U.S. courts, Bernstein Liebhard LLP reports. ... July 31, 2014, Byetta and Bydureon (an extended-release version ... claims that allege the drugs caused pancreatitis, pancreatic cancer ... these claims are pending in a multidistrict litigation underway ...
(Date:8/30/2014)... Randy Dotinga HealthDay Reporter ... five patients operated on for broken bones or other orthopedic ... study finds. Less-educated patients and patients who had ... be "doctor shoppers," said study lead author Dr. Brent Morris, ... said, the study suggests that doctors aren,t talking to one ...
(Date:8/30/2014)... Pittsburgh, PA (PRWEB) August 30, 2014 ... the result of a car accident," said one of ... constant muscle strain in her shoulder and neck area. ... we invented reduced pain and pressure, assisting in comfort ... for the patent-pending PILLOW CRADLE to support the head, ...
Breaking Medicine News(10 mins):Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 2Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 3Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 4Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 5Health News:Acne Treatment Reviews Added to Popular Treatment Website 2Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 2Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 3Health News:'Doctor-Shopping' for Painkillers Common After Broken-Bone Surgery, Study Finds 2Health News:'Doctor-Shopping' for Painkillers Common After Broken-Bone Surgery, Study Finds 3
... , WEDNESDAY, Aug. 17 (HealthDay News) -- ... than one-third of lower leg injuries treated in U.S. ... Alternative approaches to treatment, such as an emergency hotline ... emergency department resources, researchers from Massachusetts General Hospital in ...
... A co-worker,s rudeness can have a great impact on relationships ... published online in the Journal of Organizational Behavior . ... intense that, at the end of the day, it is ... the worker,s family and partner, who in turn takes the ...
... -- The risk of deep vein thrombosis -- a sometimes deadly ... surgery -- is low when preventive measures such as anti-clotting drugs ... cases of deep vein thrombosis, or DVT, that occur after general ... study, published in the Aug. 15 online edition of the journal ...
... back on current expenses and largely unable to meet essential ... to a new poll from The SCAN Foundation and the ... poll, in its second year, sought to better understand health ... current economic crisis and the rising number of Californians older ...
... TUESDAY, Aug. 16 (HealthDay News) -- Drinking moderate amounts ... dementia, according to a review of previous research. ... Medicine analyzed data from more than 365,000 people who ... 1977. Moderate drinkers were 23 percent less likely ...
... new study has shown the Flexible-Fiber CO2 laser to ... (TSC) without the,line of sight problems encountered with conventional ... Medical Center (BMC) and Boston University School of Medicine ... Neurosurgery . This is the first study to report ...
Cached Medicine News:Health News:Sprained Ankles Straining ER Resources, Study Finds 2Health News:Baylor University study finds consequences of co-worker rudeness are far-reaching 2Health News:Central Catheters May Raise Risk of Blood Clots After Surgery 2Health News:Poll finds two-thirds of California voters unprepared for costs of growing older 2Health News:Poll finds two-thirds of California voters unprepared for costs of growing older 3Health News:Poll finds two-thirds of California voters unprepared for costs of growing older 4Health News:Moderate Drinking May Help Prevent Alzheimer's, Other Dementia 2Health News:Moderate Drinking May Help Prevent Alzheimer's, Other Dementia 3Health News:Study finds flexible-fiber CO2 laser safe in endoscopic endonasal transsphenoidal surgery 2
(Date:8/29/2014)... , Aug. 29, 2014  United Therapeutics Corporation (NASDAQ: ... District Court for the District of New ... the company,s case against Sandoz, Inc. regarding United Therapeutics, ... Sheridan ruled that U.S. Patent No. 6,765,117 is ... Sandoz from marketing its generic product until the expiration ...
(Date:8/29/2014)... /PRNewswire-iReach/ -- ChemImage will present a workshop focused on ... Forensic Science Society,s 22 nd International Symposium ... Australia .  Forensic Scientists will be in ... imaging can bring to examination procedures. ... Product Development at ChemImage, will host a workshop ...
(Date:8/29/2014)... MENLO PARK, Calif. , Aug. 29, ... (OTCQB: DMPI) ("DelMar" "the Company") today announced the filing ... Company recently changed its fiscal year end to June ... its common stock on a national securities exchange in ... as filed with the United States Securities Exchange Commission ...
Breaking Medicine Technology:District Court Decision Received In Remodulin Patent Case 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 2DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 4DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 5
... England, 4th May 2007 - CeNeS Pharmaceuticals plc,(LSE: ... of an independent study in the respected scientific,journal ... 5161. CeNeS,is developing CNS 5161 as a potential ... the work that CeNeS has,already undertaken with CNS ...
... - New data from a,randomized, double-blind study ... injection) along with the oral,antibiotic minocycline reduced ... 63 percent (p=0.08) in patients with active,relapsing-remitting ... imaging (MRI), compared to those receiving,COPAXONE(R) alone. ...
Cached Medicine Technology:Independent publication supports the profile of CeNeS phase II,compound, CNS 5161 2Independent publication supports the profile of CeNeS phase II,compound, CNS 5161 3Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 2Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 3Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 4Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 5
... an extremely accurate digital A-scan system. The ... probe and fast precise algorithm enables scan ... along the visual axis. The A5500 A-scan ... monitor, built-in thermal printer, 5 different examination ...
... is extremely portable, weighing slightly more than ... system provides a large liquid crystal display. ... noise probe and fast precise algorithm enables ... probe along the visual axis. The Microscan ...
... Accurate, efficient and easy to use. The ... variety of regressive, theoretical, and adaptive IOL ... the patient. Convenient design features improve your ... hands-free operation, audible tone to minimize corneal ...
... Ultrasonic A-Scan offers so many ... package. Besides,its compact and lightweight ... measurement and easy operation.,Furthermore, it ... and manual gate.,NIDEK is proud ...
Medicine Products: